Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Up 648.8% in December

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 98,252 shares, an increase of 648.8% from the November 30th total of 13,122 shares. Based on an average daily volume of 108,651 shares, the short-interest ratio is currently 0.9 days. Currently, 5.9% of the shares of the company are short sold. Currently, 5.9% of the shares of the company are short sold. Based on an average daily volume of 108,651 shares, the short-interest ratio is currently 0.9 days.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ACXP shares. Wall Street Zen cut Acurx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Acurx Pharmaceuticals in a research note on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ:ACXP opened at $3.42 on Friday. Acurx Pharmaceuticals has a twelve month low of $3.17 and a twelve month high of $25.00. The firm has a market capitalization of $7.16 million, a price-to-earnings ratio of -0.40 and a beta of -1.25. The stock’s 50 day moving average is $4.57 and its 200-day moving average is $6.00.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.23) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.38. Equities research analysts anticipate that Acurx Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A hedge fund recently bought a new stake in Acurx Pharmaceuticals stock. O Brien Greene & Co. Inc acquired a new position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 60,000 shares of the company’s stock, valued at approximately $31,000. O Brien Greene & Co. Inc owned about 0.20% of Acurx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 11.53% of the stock is owned by institutional investors.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).